Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Acute Myeloid Leukemia
Interventions: Cladribine, Cytarabine, Gemtuzumab Ozogamicin, Recombinant Granulocyte Colony-Stimulating Factor, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride; Drug · Biological · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Concussion, Brain
Interventions: Education; Other
Lead sponsor: Stanford University; Other
Eligibility: 14 Years to 19 Years · Male only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prodromal Symptoms, Prodromal Stage, Prodromal States, Psychosis
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 13 Years to 19 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: B-cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Interventions: lenalidomide, laboratory biomarker analysis, lymph node biopsy, bone marrow aspiration, pharmacological study, flow cytometry; Drug · Other · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hodgkin Lymphoma
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Smoldering Multiple Myeloma
Interventions: Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Gingivitis, Plaque
Interventions: sodium monofluorophosphate toothpaste; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Glioma, Glioblastoma, Brain Tumor, Recurrent
Interventions: ANG1005, Bevacizumab; Drug
Lead sponsor: Angiochem Inc; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 12
States / cities: La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more

Conditions: Optical Coherence Tomography of Retina
Interventions: retinal imaging with low-cost OCT device, retinal imaging with commercial OCT device; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Infections, Bacterial
Interventions: Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Anaheim, California • Austin, Texas

Conditions: Health Behavior
Interventions: Exercise leggings; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: High Blood Pressure
Interventions: Coffee; Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 30 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG, H3K27-altered High Grade Glioma
Interventions: ACT001; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 12 Months to 39 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 12
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 9 more

Conditions: Cardiovascular Risk Factor, Heart Diseases, Inflammation
Interventions: Q CAN PLUS, Placebo; Dietary Supplement
Lead sponsor: Loma Linda University; Other
Eligibility: 29 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Brain and Central Nervous System Tumors
Interventions: semaxanib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more

Conditions: Lung Diseases, Tuberculosis
Interventions: Adherence Program, Life Skills and Self-Esteem Training Program (Attention Control Arm); Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Foot, Footwear
Interventions: Moderate Stiffness Footwear, High Stiffness Footwear; Other
Lead sponsor: High Point University; Other
Eligibility: 12 Years to 19 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Barretts Esophagus, Esophageal Cancer
Interventions: Cryospray Ablation; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hemophilia A
Interventions: Bypassing Agents, FVIII Replacement; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Santa Monica, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Glioblastoma Multiforme
Interventions: Not listed
Lead sponsor: New York Presbyterian Brooklyn Methodist Hospital; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Dehydration
Interventions: Water, Gatorade, BodyArmor, GoodSport; Other
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Myelodysplastic Syndrome
Interventions: vadastuximab talirine, Azacitidine, Placebo (for 33A); Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 34
States / cities: Gilbert, Arizona • Los Angeles, California • Aurora, Colorado + 29 more

Conditions: Veterans, Geriatric Assessment, Care-Coordination, Outpatient Care
Interventions: Comprehensive Care, Standard Care; Other
Lead sponsor: Miami VA Healthcare System; Federal
Eligibility: 65 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Meditation, Control Group
Interventions: Calm Meditation, Educational Podcast Control; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 40 Years to 64 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Comparison of Concussion Education Programs

HOPE TEAM - Clinical High Risk Group CBSST

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Genetic Study of Families With High Frequency of Hodgkin Lymphoma

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in a Population With High Plaque/Low Gingivitis and High Plaque/High Gingivitis

ANG1005 in Patients With Recurrent High-Grade Glioma

Comparative Study of High Performance Low-Cost Optical Coherence Tomography

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

Leggings With Resistance Bands on Caloric Expenditure During Exercise

Effects of High Caffeine Content Coffee on Blood Pressure in Young Adults

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors

SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy

Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents

Changes in Footwear Comfort and Performance in High School Football Players

Cryotherapy for Barrett's Esophagus and Early Esophageal Cancers

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

MRI Predictors of Response to Tumor Treating Fields

Rehydration Efficiency With Different Sports Drinks

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

Inter-Disciplinary Outpatient Care Model Providing Comprehensive Geriatric Assessment, Care-Coordination & Co-management

A Brief App-based Mobile Health and Well-being Intervention Among Middle-aged Adults